This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.

  Mobile version   RSS   Subscribe   Unsubscribe   Archive   Media Kit Jan. 11, 2012

Home   About The ATA   Join   Fellows' Corner


Dosimetric calculation of 131-I doses may be more effective than empiric doses for patients with locally advanced differentiated thyroid cancer
Clinical Thyroidology    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Radioiodine-131  has been used for over 50 years for the treatment of metastatic or persistent differentiated thyroid cancer. It is usually administered in arbitrary or emipiric doses that are based on the extent of the metastases or residual disease. Some institutions use a method called "dosimetry." More

Pregnant women benefit from beginning iodine supplementation long before pregnancy
Clinical Thyroidology for Patients    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Iodine is a mineral that we get from our diet that is important for making thyroid hormones and for normal thyroid function. It is important in adults as well as in developing babies. Worldwide, iodine deficiency is the most common cause of hypothyroidism. In the United States we rarely see this problem since our diet usually contains adequate amounts of iodine. More

Hyperparathyroidism charting in EMR can be easy

With the right tools and workflow, charting an initial consultation for Hyperparathyroidism can be very easy and quick. You can also setup and manage reminders for yearly calcium levels automatically. Click here to see the video.

Novel classes of drugs identified with antiproliferative effect in thyroid cancer
Endocrine Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Quantitative high-throughput drug screening can identify novel agents in different therapeutic categories and drugs with nonclassic chemotherapy mode of action, according to study results published online in the Journal of Clinical Endocrinology & Metabolism. More

Risk of malignancy may be higher in cytologically suspicious thyroid nodules that are smaller or multiple
Clinical Thyroidology    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Fine-needle aspiration biopsy has a high predictive value for benign and malignant thyroid nodules but has a lower predictive value for indeterminate or suspicious nodules. Clinical data was extracted from an electronic medical record from January 2004 through September 2008 of patients who had undergone FNAB and thyroid surgery for cytologically suspicious nodules. More

TSI Reporter BioAssay

•Graves’ disease is the primary cause of hyperthyroidism.

•Graves’ disease is characterized by the presence of thyroid stimulating immunoglobulin (TSI).

•Thyretain TSI Reporter BioAssay is the only commercially available IVD for the detection of TSI, the causative agent of Graves’ disease.


Can nodules with a benign ultrasound appearance be left alone without biopsy?
Clinical Thyroidology for Patients    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Thyroid nodules are very common. Some studies have suggested that up to 50 percent of individuals that have neck imaging for any reason will have a thyroid nodule. The evaluation of a thyroid nodule often includes a thyroid ultrasound and a biopsy, depending on the size of the nodule. Several studies have attempted to link certain features on the thyroid ultrasound that are found in cancerous nodules in order to help target the more concerning nodules for biopsy. More

The best treatment for hyperthyroidism
Endocrine Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Dr. Thomas Repas writes, "A 47-year-old woman came to see me regarding hyperthyroidism. She had previously been treated for hyperthyroidism due to Graves' disease eight years earlier. At that time, she decided on management with antithyroid medication. After 18 months of therapy, the methimazole was stopped. She remained euthyroid until recently." More

ATA Thyroid Weekly News Briefs
ATA does not develop, exert any editorial or other control, or guarantee the accuracy, completeness, efficacy, or timeliness, of the materials, information, advertising or promotional activities ("Content") in this publication. Inclusion of Content in this publication does not constitute or imply endorsement, agreement, recommendation, or favoring by ATA of such information or the entities mentioned or promoted herein. Use of any Content appearing or referenced in this publication or obtained from advertisers is voluntary, and reliance on it should only be undertaken after an independent review by qualified experts. ATA is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use of, reference to, reliance on, or performance pursuant to such Content.

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Julie Bernhard, Sr. Content Editor, 469.420.2647   
Contribute news

This edition of the ATA Thyroid Weekly News Briefs was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here -- it's free!
Recent issues
Jan. 11, 2012
Jan. 4, 2012
Dec. 28, 2011
Dec. 21, 2011

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063